Introduction
Clopidogrel, a thienopyridine that antagonizes ADP-mediated platelet activation, is well established in the treatment of Acute coronary syndromes (ACSs) 1, 2 and percutaneous coronary intervention (PCI). 3 The majority of ACS patients can be managed medically or with PCI; both groups require aspirin lifelong and clopidogrel for 1 year. 2, 3 However, 10-15% require surgical revascularization and concerns remain regarding the continuing use of clopidogrel until coronary artery bypass grafting (CABG). 4 Observational studies suggest an increased bleeding risk and resternotomy rates if clopidogrel is not discontinued prior to surgery. 5 Thus, current guidelines suggest that clopidogrel should be discontinued for 5 days prior to CABG when clinically feasible. 6, 7 Other reviews and meta-analysis have supported this, 8 -10 but focus predominantly patients undergoing elective CABG and not on ACS patients requiring urgent surgery. These patients are likely to be operated upon with recent clopidogrel exposure. Furthermore, registry data on current clinical practice suggest many non-urgent ACS patients undergo CABG without waiting for a clopidogrel-free period. 11 Therefore, there remains the specific question of timing clopidogrel discontinuation in the ACS patient who remains at elevated risk of repeat myocardial infarction (MI) and thromboembolic events while awaiting CABG. This ischaemia must be balanced against the bleeding risk post-operatively. This systematic review aims to determine the risk of mortality, reoperation, perioperative MI, and stroke in the ACS population undergoing surgery while on clopidogrel using all the currently available data. We provide a synthesis of the data and introduce a management algorithm.
Methods

Search strategy
The Mesh terms 'clopidogrel', 'coronary artery bypass', 'reoperation' 'haemorrhage', 'MI', and 'cerebrovascular accident' were searched in Medline and Embase databases ( Figure 1 ). This was expanded using reference lists from retrieved articles. This meta-analysis was planned, conducted, and reported in accordance with official guidelines for reporting meta-analyses of randomized and observational studies.
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Data extraction
Two reviewers reviewed all abstracts and extracted the data from the full texts of each eligible study (shown in the results tables). Disagreements regarding data collection were resolved by a third author.
Eligibility criteria
The exposure of interest was clopidogrel use prior to CABG (CL) with the control group being clopidogrel naive or those with a drug-free period prior to surgery (NC). The outcomes were reoperation rates, mortality, postoperative MI, and stroke. Studies were included if they reported at least one outcome measure in such a way that a comparison could be drawn.
Definition of endpoints
Mortality was accepted as reported. Reoperation specifically for bleeding was sought but not always specifically reported. Myocardial infarction was defined by studies as 'perioperative' or 'postoperative': few gave precise definitions or how MI was diagnosed. Cerebrovascular accident was defined as reported by the studies. Both haemorrhagic and ischaemic stroke were accepted as few differentiated.
Quality assessment
A star rating system was developed to assess the importance of ACS patients in each study (Box 1). 15 Newcastle Ottawa quality 16 scoring assessment produced identical results as another published meta-analysis 8 and is not presented to avoid redundancy.
Risk of bias analysis
A risk of bias analysis was performed, specifically assessing allocation concealment, blinding, assessment of incomplete data, and freedom from selective reporting. Only four studies are randomized controlled trials (RCTs) and met criteria for freedom from bias. 27, 30, 40, 45 The remainder observational studies cannot exclude bias and score poorly. 
Statistical analysis
Our meta-analysis combines the odds ratio (OR) estimates for mortality, reoperation, MI, and stroke for each study using the random effects model, which accounts for both within-and between-study variation. 17 Aggregation of the overall rates of the outcomes of interest was performed with the Mantel -Haenszel Chi-square test. 18 The quantitative and graphical methods used to assess, explain, and account for determinants of meta-analytical validity, heterogeneity, and bias have been described previously. 15, 19 Uni-and multivariate meta-regression was performed for the main outcomes of mortality, reoperation, post-operative MI, and stroke using the logarithm of the OR as the dependent variable. Interaction analysis was performed creating interaction terms between the variable ACS status and the following variables: year of study, the use of on-pump surgery, patient urgency status and use of concomitant antiplatelet agents, including aspirin and GPIIbIIIa antagonists. All the statistical tests were two sided with a threshold of significance being a P , 0. 
Results
Study details
The search strategy is presented in Figure 1 . Thirty-four studies were included with a total of 22 584 patients ( Table 1) . 5,11,20 -51 The majority are not blinded with patients treated clinically with full knowledge of prior clopidogrel exposure. Twenty-nine studies were observational reflecting on local experience: 17 were retrospective 5,11,22,23,28,32,34,35,37,39,41 -44,48 -50 and 12 were prospective. 20,21,24 -26,29,31,33,36,38,47,51 Three studies were subgroup analyses from larger ACS RCTs. 27, 40, 45 Two studies were small RCTs assessing clopidogrel exposure before surgery. 30, 46 Inclusion and exclusion criteria were not uniformly reported 11, 22, 27, 29, 39, 40, 41, 44, 45, 50 making it unclear if higher risk patients were included. Details regarding the operative procedure and pro-coagulant use were greatest in the smaller observational studies. Table 2 shows clopidogrel use and recent ACS status, aspirin and GPIIbIIIa exposure. Fourteen studies assessed patients in whom clopidogrel was stopped ≤5-7 days prior to surgery ('clopidogrel' CL), comparing them with clopidogrel naive patients and those with a drug-free 'washout' period ('no clopidogrel' NC).
Recent loading doses of aspirin and clopidogrel are rarely reported, but it is presumed that most patients will load with 300-600 mg. Control populations had variability in their use of aspirin; some control groups had no recent antiplatelet use. 23, 28, 30, 35, 37, 38, 49 Reporting of aspirin use overall was variable:
some studies did not report aspirin use. 22, 40, 48, 50 The proportions of control patients with recent clopidogrel exposure but a washout period of 7 days were not reported. Overall, insufficient published data were available to determine whether there was an impact according to the precise day that clopidogrel was stopped. It is also unclear whether clopidogrel naive patients had recent ACS. The use of GPIIbIIIa inhibitors, heparins, and thrombolysis was under reported. Patient age and gender distribution was matched between CL and NC groups. Table 3 shows the quality assessment of the studies. The median was 10. 
Assessment of mortality
Those undergoing CABG with recent clopidogrel exposure have an increased mortality compared with the control populations used (OR 1.6, 95% CI 1.30-1.96, P , 0.00001). Control populations were often elective stable patients. Univariate meta-regression showed that there were marginal trends of the following variables on the log-OR of mortality: study sample size (P ¼ 0.068), female sex (P ¼ 0.055), and a significant effect for ACS status in studies recruiting more than 50% patients with ACS (P ¼ 0.042) ( Figure 2 ). However, when assessed in a multivariate analysis, none of variables was found to have a significant effect including on-pump surgery, renal impairment, weight, aspirin use, glycoprotein use, study quality, aprotonin, and number of vessels grafted. Subgroup analysis of studies recruiting only ACS patients showed a similar increased mortality rate (OR 1.44, 95% CI 0.97-2.1, P ¼ 0.07). The smaller subgroup size has reduced the level of statistical significance. Interaction analysis showed a significant effect of the interaction between urgency of the surgery and recruitment of less than 50% of ACS patients into the study (P ¼ 0.03). Following univariate meta-regression, it was found that the effect size of mortality in studies where ACS patients are not evenly distributed across the CL and NC groups may be affected by the urgency status of the surgery. This is an expected finding. No significant interaction effect was seen when the proportions of ACS patients were balanced in both CL and NC groups and when only ACS was recruited (P . 0.05). Therefore, the ACS status of patients may drive an increase in mortality on those having urgent surgery with recent clopidogrel exposure. (8) 54 (8) 12 13 Retro, retrospective study; pro, prospective study; RCT, randomized controlled trial. A, pre-operative MACE; B, reoperation for bleeding; C, reoperation for other; D, units of RBC transfused; E, units of Platelets transfused; F, units of FFP; G, units of blood products; H, chest drain output over 12 h; I, chest drain output over 24 h; J, mortality; K, conventional CABG; L, off-pump CABG; M, CABG and valve surgery; N, redo CABG; P, emergent surgery; T, valve surgery alone; V, preoperative exposure to warfarin; W, preoperative exposure to GPIIbIIIa; X, bleeding disorder; Y, end-stage renal disease; Z, end-stage heart failure. ns, not stated; na, not applicable. Safety of clopidogrel being continued until the time of CABG in patients with ACS coronary syndrome status did influence the effect size of MI in univariate analysis (P ¼ 0.04), but this was not significant in multivariate analysis. No significant effect from interaction was seen between ACS status with urgency, on-pump surgery, and GPIIbIIIa use (all P . 0.05). No significant interaction effect was seen on the log OR of MI between studies with ,50% and .50% ACS patients recruited and the variables: year of study, on-pump surgery, urgency status, and use of concomitant aspirin or GPIIbIIIa antagonists.
Assessment of postoperative stroke and major adverse cardiovascular event
Fewer studies report postoperative stroke rates. One study specifically described transient ischaemic attacks (TIA). 31 It is unclear whether other studies included patients having TIA as 'stroke' or were included at all. Directionally, there is an increase in the stroke rate in the CL group, but it is not significant (OR 1.46, 95% CI 0.91-2.33, P ¼ 0.11). This is also true in the studies recruiting 100% ACS patients (OR 1.23, 95% CI 0.66-2.29, P ¼ 0.52). Acute coronary syndrome status was a predictor of stroke in univariate meta-regression analysis ( p ¼ 0.04) and GPIIbIIIa antagonist use demonstrated marginal significance (P ¼ 0.065).
Neither was significant in multivariate analysis. No other significant interaction terms were identified. Assessing a combined major adverse cardiovascular event (MACE) rate (MIs, stroke, and death) after CABG reveals that there is no increased risk in patients with recent clopidogrel exposure (Figure 4 ; OR 1.10, 95% CI 0.87-1.41, P ¼ 0.43). Caution is required in interpreting this statistic because it is post hoc assessment of published studies but it is reassuring.
Assessment of chest drain output
The majority of the studies are not adequately powered to find differences in rare outcomes, including reoperation and mortality. Many focus on chest drain output either at 12 or 24 h. Drain output follows a skewed distribution in the majority and is increased in the CL group (mean difference of 219 mL, 95% CI 129-308 mL, P , 0.00001). However, there is marked heterogeneity (I 2 97%). Based on surgical experience (using the year that OPCAB studies show a mean difference of drain output of 154 ml (95% CI 280 to 389, P ¼ 0.20) with no clinically significant difference in drain output between NC and CL groups. However, heterogeneity is not removed by any stratification, reflecting the diverse patient population, recording, and reporting of drain output and surgical technique.
Assessment of transfusion
Blood transfusion has been reported as the percentage of patients receiving transfusion, or the units or millilitres given. Transfusions were converted into units where possible. Studies had differing triggers for transfusion creating heterogeneity. Larger RCTs have used variations of 'TIMI major bleeding' and do not report transfusion. The majority report packed red blood cell (RBC) transfusion post-operatively. Clopidogrel increases RBC transfusion (by 1.1 units, 95% 0.58-1.64 units, P , 0.0001; Figure 6 ), platelet (by 0.18 units, 95% CI 0.14 -0.21, P , 0.00001), and FFP (by 0.49 units, 95% CI 0.14 -0.84, P ¼ 0.006) transfusion requirements. However, heterogeneity for all three variables (I 2 94 -99%) is raised, reflecting the weakness of this outcome measure.
Assessment of reoperation
Reoperation rates are increased in the CL group compared with NC group (OR 2.32, 95% CI 1.76-3.06, P , 0.00001). As (Figure 7) . Meta-regression showed no significant effect on the log odds of reoperation from renal impairment, weight, aspirin use, female sex, quality of study, sample size, on-pump surgery, urgency status, number of grafts, and aprotonin use (all P . 0.05). The year of surgery and ACS status had a significant effect in univariate analysis (P ¼ 0.01 and P ¼ 0.02, respectively) with a marginal significance in multivariate analysis for the year of surgery, with higher rates of reoperation seen in earlier studies (P ¼ 0.095). No significant effect from interaction variables was identified.
Assessment of ITU stay
Clopidogrel does increase ITU stay length by a mean difference of 0.31 days (95% CI 0.06-0.56, P ¼ 0.01), but this is unlikely to be clinically significant. Duration of ITU stay is highly variable according to local protocols and bed availability for step-down. Importantly, in many of the studies suggesting large drain output and transfusion requirement, no significant ITU or hospital stay differences were seen suggesting that the clinical impact is small. Figure 5 Chest drain output stratified according to the operating experience (year of procedure). Studies explicitly reporting chest drain output are included and shown. Englberger et al., 26 Hekmat et al. 28 and von Heymann et al. 35 are not included because they do not state when data collection occured. Year of procedures are given in Table 1 .
Recent RCT data
Within the PLATO study, 1899 patients underwent CABG with 1261 patients having surgery within 7 days of clopidogrel or ticagrelor. 52 No aspirin only group was included in PLATO and thus it is not included in our meta-analysis. In 629 patients exposed to clopidogrel before CABG, post-operative MI occurred in 5.7% (35 patients), stroke in 2.1% (11), and all-cause mortality in 9.7% (58) . Reoperation due to bleeding was 3.3% (21) . Median chest tube output within 24 h was 540 mL (320 -810 IQR). 56.5% (351) had transfusion within 7 days of CABG (51.9% packed red cells or whole blood, 17.5% platelets, and 24.1% FFP). Nearly, all the bleeding events occurred within 24 h post-CABG. 52 Overall, these findings were consistent with ACUITY study featured in this analysis. The design of the TRITON-TIMI-38 trial assessing the efficacy of prasugrel compared with clopidogrel in ACS meant that few patients underwent CABG with a recent dose of either drug. 53 In the clopidogrel arm, 189 patients underwent CABG with 3.2% (6) having TIMI major bleeding.
Discussion
This meta-analysis demonstrates that present guidelines are based on limited evidence which do not definitively determine the safety of continuing clopidogrel until CABG in ACS patients. Comparisons have been made of ACS patients requiring urgent surgery with more stable and elective cases. While it is accepted that ACS patients must be operated on aspirin, 54, 57 many studies have compared bleeding outcomes and reoperation in ACS patients on dual antiplatelet therapy to stable patients on none. 23, 28, 30, 35, 37, 38, 41, 49 Furthermore, none has considered recent loading doses, known to influence bleeding, 55 and few consider the implications of GPIIbIIIa inhibitors, commonly used alongside clopidogrel in high-risk ACS. The majority of the studies are small and retrospective with limited subgroup analysis from RCTs. The bleeding and transfusion data are heterogeneous and with potential for treatment and ascertainment bias. This meta-analysis demonstrates the need for a RCT assessing different discontinuation times prior to CABG to definitively answer the Table 1 .
Safety of clopidogrel being continued until the time of CABG in patients with ACS question. In the meantime, the data do demonstrate that many patients have undergone CABG safely with recent clopidogrel exposure and this practice can continue in expert hands in ACS patients who need to continue clopidogrel.
Mortality and reoperation
Accepting its limitations, the data suggest that continuing dual antiplatelet therapy until the day of CABG reduces the risk of recurrent ischaemic events in ACS patients and reduces MI post-operatively. However, there may be opposing effect in post-operative stroke. While mortality and reoperation rates are increased after recent clopidogrel exposure, event rates are still low. Multivariate meta-regression including interaction terms did not find a strong signal that ACS status and urgency of patients drove the mortality increase but even meta-analysis has limited power to detect such signal. Overall MACE rates did not appear to be significantly increased in the clopidogrel group. Reoperation rates are likely influenced by the experience of operating on clopidogrel and correspondingly recent cohorts have seen a reduction in reoperation rates. 46, 50, 51 In this meta-analysis, taken as a collective registry, a 2.87% mortality rate is seen in those on clopidogrel (in a total of 6019 patients) vs. 1.87% in a mixed control population of 16 565 patients. Reoperation occurs in 3.9 and 1.85% patients, respectively. These rates are driven by the steep learning curve of earlier surgical experience (most studies reflect early experience, circa 1998-2003 20 -27,29 -35,42,44,49 ) and some recruitment bias in the larger studies. 5 They are within acceptable rates of resternotomy of 2-6% from the pre-clopidogrel era. 56 The case volume and size of the surgical faculty must also influence reoperation rates. Rigorous attention to haemostasis is required because half of all reoperations reveal a surgical bleeding point suggesting inadequate technique. 25 Generalized ooze represents the consequences of dual antiplatelet therapy and responds to blood products. Few studies categorize the findings on reoperation. Previously, surgeons resisted operating on aspirin but adapted with great success making it the standard of care. 57, 58 It is expected that adaption to operating on aspirin and clopidogrel will also occur.
Postoperative stroke
Directionally, there appears to be an increase in stroke, although it is not statistically significant. We expect haemorrhagic stroke in those on clopidogrel when exposed to bypass and full anticoagulation. However, stroke has been poorly reported in the studies and an increase in TIAs and embolic strokes is difficult to interpret given dual antiplatelet therapy should reduce thrombus. The wide confidence intervals seen likely reflect the small numbers of rare events. 
Postoperative bleeding and transfusion
Postoperative bleeding and chest-drain output remain a serious concern. However, as an outcome measure, it is highly variable with some elective series reporting higher levels of output than that seen in the clopidogrel-exposed patients assessed here. 59 Adverse outcomes are more associated with blood product transfusion than anaemia post-CABG, 60 and minimizing transfusion is essential. Intra-operatively, good haemostasis and appropriate use of platelets will reduce transfusion requirements. Aprotonin may yet find a new role in patients with clopidogrel exposure. 61 Algorithms reduce transfusion rates even in the setting of clopidogrel exposure 24 and should be encouraged given that transfusion is more strongly associated with the performing surgeon than clopidogrel exposure. 62 Clearly, transfusion is a surrogate marker and future studies should focus on hard outcomes.
Pre-operative infarction risks
Patients with ACS have elevated risks of re-infarction prior to revascularization. Patients delayed for a clopidogrel-free period ('washout') can suffer prolonged inpatient waits for CABG, which in the UK is often much greater than 5 days and may be weeks. 63 Re-infarction during this time may force emergency angioplasty or intra-aortic balloon pump therapy, with potentially suboptimal long-term results for those with established surgical disease. Discontinuation of clopidogrel does trigger a real 'rebound phenomena' 64 and even in stable CAD without the presence of fresh thrombus, early discontinuation of antiplatelets increases the incidence of MI within 10 days. 65 While anecdotally many patients have further MIs while awaiting CABG after clopidogrel withdrawal, few studies report the MACE rate for this period. In CURE, patients awaiting CABG having had clopidogrel had numerically lower MACE rates than the placebo group (2.9 vs. 4.7%, 1.8% risk reduction, RR 0.56, 95% CI 0.29-1.08). 27 Those having clopidogrel withdrawn are likely exposed to this increased 1 -2% risk of MI. Combining the bleeding risk and MACE reduction, CURE suggested 18 pre-CABG events per 1000 patients treated were prevented by treating with clopidogrel prior to CABG. 27 In a small study randomizing ACS patients to stopping clopidogrel prior to CABG, 12.5% of the group stopping clopidogrel had an MI during the 5-day wait for CABG. 30 The observational studies do not report the MACE rate prior to CABG; these patients may not even enter the surgical registry. There is a need for accurate data to be collected, ideally in an RCT setting. While we await such data, we suggest high-risk patients undergo CABG at the earliest opportunity without a delay for washout and accepting a small increase in mortality and reoperation when compared with elective cases. Clopidogrel should be reinstituted after CABG as soon as chest drain output allows to protect from further events and improve graft survival.
66,67
Anti-platelet and genetic testing
Significant literature has been dedicated to the inter-individual variability in response to clopidogrel. Daily platelet-function testing may guide antiplatelet therapy and help find an operating window based on platelet reactivity. 68 -70 Genetic testing may help identify variants of liver enzymes: CYP2C19*2 carriers are hypo-responsive to clopidogrel predisposing recurrent ischaemia, while CYP2C19*17 carriers are hyper-responsive predisposing bleeding. 71 In reality, clinical decisions may be forced in urgent cases, but these tests may gain utility in more elective cases.
The future: new antiplatelet agents
The role of third-generation thienopyridines is likely to increase. Prasugrel use prior to CABG lead to a 15% absolute increase in major bleeding compared with clopidogrel (18.8 vs. 2.7%, P ¼ 0.003). 72 This dramatic increase suggests that a prasugrel-free period is mandated before CABG. In contrast, PLATO suggested ticagrelor substantially reduced mortality after CABG compared with clopidogrel while maintaining an equivalent bleeding rate. The mechanisms remain undetermined. 73 Shorter-acting reversible antiplatelet agents, such as the oral ticagrelor, 52 or the intravenous cangrelor may have a role in bridging ACS patients from the acute phase, admission, and investigation until surgery can be performed. This will be delineated in the BRIDGE trial (NCT00767507). 74 
Clinical implications: a new algorithm
The paradigm continues to be a balance between the risk of preoperative ischaemia and peri-operative bleeding. For elective patients without ACS, the bleeding risk is more important and clopidogrel should be stopped for 5 days as per current guidance. However, we suggest ACS patients with surgical anatomy have CABG at the earliest clinical opportunity, while on clopidogrel without delay for washout (Box 2). Those discussed at a multidisciplinary 'Heart Team' meeting and considered at high bleeding risk or those having redo surgery should have clopidogrel withdrawn cautiously. Platelet function testing may help determine an operating window.
In those with drug-eluting stents less than 1 year old, surgeons should consider operating on clopidogrel. If the surgical risk is considered too high, intravenous tirofiban with or without heparin may provide bridging cover until RCTs demonstrate an alternative approach. 75 Box 2 Algorithm for treating acute coronary syndrome patients that require coronary artery bypass grafting 
Limitations
Only five RCTs were included in this analysis and only two focused on addressing the issue of clopidogrel use prior to CABG. 30, 46 Both are too small to assess relatively rare outcomes. Three studies are subgroups of larger RCTs and may contain bias as data collection did not focus on the outcomes assessed here. 27, 40, 45 Only two specifically randomized to clopidogrel vs. no clopidogrel 27, 40 and only one sufficient sample size to provide outcome data. 27 The remaining studies are small to medium sized registries, with potential for bias. Without access to the individual patient data, we cannot make a detailed assessment of confounders. We are reliant on the original publication's summary statistics. Heterogeneity prevents firm conclusions and highlights the variability in practice and outcomes throughout the world. Viewed positively, this meta-analysis strongly encourages a definitive RCT to specifically answer this question. Based on the expected major adverse (death, MI, CVA) event rate of 5% a trial would require at least 2000 patients with 80% power to detect a relative risk reduction of 0.5. Given adverse outcome rates are low, detecting more realistic but smaller relative risk reductions will necessitate larger sample sizes. This would require international support.
Conclusions
Clopidogrel is well established in ACS, but current guidelines on stopping clopidogrel in ACS patients prior to CABG are based on limited data. Clopidogrel reduces MI in ACS patients prior to revascularization but does increase bleeding. Modern surgical techniques should aim to reduce reoperation rates and minimize unnecessary transfusion. A registry of patients having major cardiovascular events while awaiting inpatient CABG is required. We strongly urge a large international RCT to assess the question of clopidogrel in ACS patients undergoing CABG. Until then we support selected ACS patients undergoing CABG without stopping clopidogrel.
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